Obama, McCain united against drug costs

Despite a lack of socialized medicine in the United States, the U.S. government pays a hefty 45 percent of the total expenditure of healthcare, and drugs represent a large percentage of the costs. Both Obama and McCain are prioritizing big pharma in their campaign goals to cut costs, which might be part of the reason for industry stock drops. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.